Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
51. |
ECCT/13/04/08 | Switching At Low HIV-1 RNA Into Fixed Dose Combinations SALIF Protocol Number: TMC278IFD3002 Amendment INT-1 |
Principal Investigator(s) 1. Edwin Onyango WERE 2. Milton Tony OMONDI 3. Gina OUATTARA 4. Gaudensia Nzembi MUTUA 5. Reena SHAH Site(s) in Kenya 1. Aga Khan University Hospital (Nairobi City county) 2. KEMRI/Walter-Reed Project Kombewa (Kisumu county) 3. Partners in Prevention (Uasin Gishu county) 4. Kenya AIDS Vaccine Initiative - KNH (Nairobi City county) 5. Kenya AIDS Vaccine Initiative - Kangemi (Nairobi City county) |
30-07-2012 |
View |
52. |
ECCT/13/04/09 | Short-course RPT/INH for latent TB in HIV-infected individuals Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals with Latent Tuberculosis Infection |
Principal Investigator(s) 1. Deborah C. Langat Site(s) in Kenya 1. Kenya Medical Research Institute Walter Reed Project Clinical Research Centre (Kericho county) 2. Moi University Clinical Research Centre (Uasin Gishu county) |
26-03-2013 |
View |
53. |
ECCT/13/05/01 | Use of the Shang Ring device in all four childhood age groups in the African population |
Principal Investigator(s) 1. Quentin David Awori Site(s) in Kenya Homa Bay District Hospital |
18-04-2013 |
View |
54. |
ECCT/13/05/02 | An open-label randomized controlled trial of the efficacy and safety of Clindamycin plus quinine compared with artemether-lumefantrine for the treatment of children with uncomplicated falciparum malaria in western Kenya |
Principal Investigator(s) 1. CHARLES OWUORA OBONYO Site(s) in Kenya Ahero Sub-district Hospital |
10-10-2012 |
View |
55. |
ECCT/13/07/01 | HIVCORE004/N004 A phase I/IIa clinical trial of universal HIV-1 vaccines pSG2.HIVconsv DNA, MVA.HIVconsv and ChAdV63.HIVconsv in combined regimens in healthy HIV-1/2-negative adults in Nairobi. |
Principal Investigator(s) 1. Prof. Walter Godfrey Jaoko Site(s) in Kenya KAVI-KANGEMI RESEARCH SITE |
19-06-2013 |
View |
56. |
ECCT/13/07/03 | Pharmacokinetic and pharmacodynamic studies of efficacy, tolerability and safety of higher dosage rifapentine for treatment of tuberculosis |
Principal Investigator(s) 1. Dr Lena Matata Site(s) in Kenya KEMRI-CDC |
07-12-2011 |
View |
57. |
ECCT/13/07/04 | Advanced Kapsosis Sarcoma Chemotherapy Regimens A Randomized Comparison of Three Regimens of Chemotherapy with Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings |
Principal Investigator(s) 1. Josphat Kosgei Site(s) in Kenya 1. WRP/KEMRI - Kericho (Kericho county) 2. AMPATH - MOI University Teaching Hospital Eldoret CRS (Uasin Gishu county) |
07-08-2012 |
View |
58. |
ECCT/13/07/05 | Single Dose Escalating, Single-blind Phase 1 Trial in Healthy Male Volunteers to Evalute the Safety, Tolerability and the Pharmacokinetics of Oleylphosphocholine. |
Principal Investigator(s) 1. Rashid Ravasco Juma Site(s) in Kenya KEMRI Centre for Clinical Research |
25-06-2013 |
View |
59. |
ECCT/13/08/01 | M72/AS01 E A phase IIb, double-blind, randomised, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of GSK Biologicals’ candidatetuberculosis (TB) vaccine GSK 692342 against TB disease, in healthy adults aged 18-50 years, living in a TB endemic region. |
Principal Investigator(s) 1. Dr Videlis Nduba Site(s) in Kenya KEMRI-CDC |
06-08-2013 |
View |
60. |
ECCT/13/08/02 | MalPaC Trial Comparing drug-regimens for clearing parasites in Phase IIb trial designs prior to PCR monitoring for Plasmodium falciparum infection. |
Principal Investigator(s) 1. Caroline Amolo Ogwang 2. Francis Maina Ndung\'u Site(s) in Kenya Junju |
29-07-2013 |
View |